Dimethicone

證據等級: L5

預測適應症: 0 個

Dimethicone: Drug Repurposing Evaluation Report

One-Sentence Summary

Dimethicone (simethicone) is a silicone-based anti-foaming agent widely used for the relief of gastrointestinal gas and bloating, and as a skin protectant in topical formulations. The TxGNN model did not generate any predicted new indications for this compound. With no repurposing candidates and significant data gaps in safety and mechanism of action, this drug currently does not have an actionable repurposing pathway.

Quick Overview

Item	Content
Original Indication	Not specified in regulatory data (commonly used as anti-flatulent / skin protectant)
Predicted New Indication	None — no predictions generated by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions, no supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	11
Recommended Decision	Hold

Why Were No Predictions Generated?

Dimethicone (polydimethylsiloxane) is an inert silicone polymer that acts primarily through physical mechanisms — it reduces the surface tension of gas bubbles in the gastrointestinal tract, allowing them to coalesce and be expelled more easily. In topical applications, it serves as a skin protectant and emollient by forming a barrier on the skin surface.

Because dimethicone is pharmacologically inert (it is not absorbed systemically and does not interact with biological targets), TxGNN’s knowledge graph may lack meaningful drug–target–disease edges to generate repurposing predictions. The absence of a defined molecular mechanism of action (MOA) and the lack of known biological targets significantly limit the model’s ability to identify new therapeutic applications through network-based reasoning.

Additionally, detailed mechanism of action data was not available in the evidence pack. Without target-level data in DrugBank or comparable databases, the knowledge graph cannot establish the mechanistic links necessary for credible repurposing predictions.

Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indications to evaluate).

Literature Evidence

Currently no related literature available (no predicted indications to evaluate).

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Details not available in regulatory data)	—	—	—

Note: 11 registrations were identified in the NPRA database for Dimethicone, but detailed product information (authorization numbers, product names, dosage forms, and approved indications) was not included in the evidence pack. Please consult the NPRA Quest database for complete registration details.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack. Dimethicone is generally considered to have a favourable safety profile due to its non-systemic pharmacological nature.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN did not generate any repurposing predictions for Dimethicone. This is likely due to the drug’s pharmacologically inert nature — it acts through physical rather than biological mechanisms, resulting in insufficient drug–target–disease connections in the knowledge graph for meaningful predictions.

To reassess, the following would be needed:

Complete DrugBank MOA and target data to determine if any biological interactions exist
Retrieval of full NPRA registration details (authorization numbers, approved indications, dosage forms)
Package insert data (warnings, contraindications) to complete the safety profile
Consideration of whether Dimethicone-containing combination products might have repurposing relevance (the active co-ingredients, rather than Dimethicone itself, may be the candidates of interest)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.